Dexmedetomidine (Igalmi)

Small molecule

Also known as BXCL501

Approvedregulatory verdict

Evidence outlook

Approved: the acute treatment of agitation associated with schizophrenia or bipolar I or II... (FDA)

This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

track record: Reliable signal

Also in development:Bipolar Disorder · Phase 3Alzheimer's Disease Agitation

Also approved (1)
US
  • IGALMI is indicated for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Product first approved 2022FDA label

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (5)
Bipolar Disorder
Schizophrenia
Other / comorbidity
NCT05665088 · BioXcel Therapeutics Inc
2022-12-05 – 2023-09-11 · Agitation, Dementia
What this study did
NCT05271552 · BioXcel Therapeutics Inc
2022-04-27 – 2023-04-21 · Agitation, Dementia
What this study did
Phase 2 (4)
Bipolar Disorder
NCT07116694 · BioXcel Therapeutics Inc
2025-06-19 – 2025-10-07 · Bipolar I Disorder, Bipolar II Disorder, Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders, Psychomotor Agitation
What this study did
Other / comorbidity
NCT06943404 · University of North Carolina, Chapel Hill
2026-02-23 – 2026-09-29 · Acute Stress Reaction, Acute Stress Disorder, Post-traumatic Stress Disorder
What this study did
NCT05276830 · BioXcel Therapeutics Inc
2022-02-08 – 2022-04-01 · Agitation, Dementia
What this study did
NCT05313386 · BioXcel Therapeutics Inc
2021-02-23 – 2022-02-21 · Agitation, Delirium
What this study did
Phase 1/2 (3)
Other / comorbidity
NCT05712707 · New York State Psychiatric Institute
2023-02-28 – 2027-02-28 · Opioid Use Disorder, Opioid Withdrawal
What this study did
NCT04251910 · BioXcel Therapeutics Inc
2019-12-27 – 2022-01-24 · Agitation,Psychomotor, Dementia
What this study did
NCT04470050 · BioXcel Therapeutics Inc
2020-06-09 – 2021-02-18 · Opioid Withdrawal
What this study did
Phase 1 (5)
Bipolar Disorder
NCT05025605 · BioXcel Therapeutics Inc
2021-08-27 – 2027-12-31 · Schizophrenia, Schizo-Affective Disorder, Schizophreniform; Schizophrenic, Bipolar Disorder I, Bipolar Disorder II
What this study did
Schizophrenia
NCT03708315 · Yale University
2020-03-09 – 2023-05-26 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT04010305 · BioXcel Therapeutics Inc
2019-05-22 – 2019-07-31 · Agitation, Schizophrenia
What this study did
Other / comorbidity
NCT06335407 · Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
2025-07-28 – 2027-04-30 · Alcohol Use Disorder (AUD), Post Traumatic Stress Disorder (PTSD)
What this study did
NCT04827056 · Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
2021-11-09 – 2023-06-02 · Alcohol Use Disorder (AUD), Post Traumatic Stress Disorder (PTSD)
What this study did
Phase 4 (2)
Bipolar Disorder
NCT05974527 · Brigham and Women's Hospital
2023-09-01 – 2026-06-30 · Agitation, Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders, Bipolar Disorder
What this study did
NCT06041646 · BioXcel Therapeutics Inc
2023-10-02 – 2024-04-29 · Bipolar Disorder, Schizophrenia, Agitation,Psychomotor, Schizo Affective Disorder, Schizophreniform Disorders
What this study did

Competitive landscape

This drug's own stage for Alzheimer's Disease Agitation: Stage not on record. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Dexmedetomidine (Igalmi): this drugStage not on recordSmall moleculeAlpha-2 adrenergic receptor (agonist)not yet gradedNo reviewed efficacy summary in this indication
Dextromethorphan / Bupropion (Auvelity)ApprovedSmall moleculesigma-1/NMDA, Dopamine/norepinephrine transporterReliable signal
NCT05557409: Change in CMAI total score, baseline to Week 5 (ADVANCE-2): -13.8 points AXS-05 vs -12.6 points placebo; did not reach statistical significance missed
NCT03226522: Change in CMAI Total Score (5 weeks): AXS-05 -15.4 score on a scale (Standard Error 1.25) vs Bupropion -10 score on a scale (Standard Error 3.02) vs Placebo -11.5 score on a scale (Standard Error 1.1)
DeulumateperonePhase 2Small moleculeSerotonin 5-HT2A / dopamine D1-D2 receptornot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Dexmedetomidine (Igalmi) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
February 2027 (1)
Phase 1Alcohol Use Disorder (AUD), Post Traumatic Stress Disorder (PTSD)Recruiting
Est. primary completion 2027-02-27 · NCT06335407 · CT.gov ↗
What to watch
July 2027 (1)
Phase 1SchizophreniaRecruiting
Est. primary completion 2027-07-31 · NCT05025605 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

16 November 2026ApprovalFDA approves IGALMI for at-home use
US, FDA · Source ↗
14 January 2026Filing submittedsNDA submitted for at-home IGALMI
US, FDA · Source ↗